Zoonotic & Vector-Borne Diseases

>

Latest News

Merck Launches Phase 3 Trial of Single-Dose Dengue Vaccine Candidate V181
Merck Launches Phase 3 Trial of Single-Dose Dengue Vaccine Candidate V181

June 16th 2025

Evaluating safety and efficacy against symptomatic, virologically confirmed dengue in children and adolescents.

Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children
Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children

June 5th 2025

Disruption of Natural Ecosystems and Risk of Zoonotic Virus Spillover
Disruption of Natural Ecosystems and Risk of Zoonotic Virus Spillover

May 21st 2025

New Report Calls For Funding Treatments, Greater Emphasis on Chronic Lyme Disease
New Report Calls For Funding Treatments, Greater Emphasis on Chronic Lyme Disease

May 14th 2025

FDA and CDC Recommend Pause on Chikungunya Vaccine IXCHIQ for Adults 65 and Older
FDA and CDC Recommend Pause on Chikungunya Vaccine IXCHIQ for Adults 65 and Older

May 12th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.